Telix Pharmaceuticals is growing revenue 49% year-over-year with analyst consensus implying 86% upside to $17.77 and high asymmetry of 9.7, but the quality score of 2.6 is deeply below the investment floor and the company is cash-flow negative, making this a speculative recovery story.
Thesis pillars
- High Asymmetry Analyst Upside→Stable
- Rapid Revenue Growth→Stable
- Quality Below Floor Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Telix Pharmaceuticals Limited (TLX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.25: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing... Read more
Sell if holding. Engine safety override at $10.25: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.5/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-26Recent Developments — Telix Pharmaceuticals Limited
Latest news
- NEWS Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journa — benzinga Jul 21, 2026 positive
- NEWS Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B — benzinga Jul 21, 2026 positive
- NEWS Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY — benzinga Jul 21, 2026 positive
- NEWS Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON Study — benzinga Jul 20, 2026 positive
- NEWS Citigroup Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $22 — benzinga Jul 7, 2026 positive
Generated 2026-07-26T09:23:04Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.25: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.86. Score 6.5/10, moderate confidence.
Take-profit target: $17.79 (+74.1% upside). Prior stop was $9.86. Stop-loss: $9.86.
Quality below floor (2.6 < 4.0).
Telix Pharmaceuticals Limited trades at a P/E of N/A (forward 50.8). TrendMatrix value score: 7.2/10. Verdict: Sell.
What does Telix Pharmaceuticals Limited do?Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and...
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen; and Regeneron Pharmaceuticals, Inc. for the development of radiopharmaceutical therapies and the joint development and commercialization of oncology programs. The company was founded in 2015 and is headquartered in North Melbourne, Australia.